{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:46:45Z","timestamp":1787068005813,"version":"build-2736575974"},"reference-count":118,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: HyperCKemia, defined as elevated serum creatine kinase, commonly reflects muscle injury but may also indicate underlying metabolic disease. Metabolic aetiologies, including glycogen storage disorders, fatty acid oxidation defects, mitochondrial cytopathies, and purine metabolism disorders, are clinically important owing to diagnostic complexity, therapeutic implications, and potential reversibility. Objective: To summarise current evidence on metabolic causes of hyperCKemia in adults, with emphasis on disorders of carbohydrate, lipid, and purine metabolism and mitochondrial disease. Methods: Semi-systematic narrative review of pathophysiology, clinical features, diagnostic approaches, and management of metabolic disorders associated with hyperCKemia. Results: Metabolic myopathies often present with nonspecific or exercise-related symptoms, with creatine kinase levels ranging from mild-to-severe elevations. Conditions such as McArdle disease, carnitine palmitoyltransferase II deficiency, and mitochondrial cytopathies demonstrate characteristic metabolic vulnerabilities leading to episodic or persistent hyperCKemia. Medications, including statins and antiretrovirals, may precipitate symptoms in predisposed individuals. Diagnosis requires a structured, multidisciplinary approach incorporating biochemical testing, genetic analysis, functional studies, and muscle biopsy. Many causes are amenable to targeted therapy, including dietary modification, endocrine correction, and medication withdrawal. Conclusion: Metabolic causes of hyperCKemia are under-recognised but clinically significant. Early identification allows targeted treatment and prevention of complications.<\/jats:p>","DOI":"10.3390\/jcm15052070","type":"journal-article","created":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T08:58:45Z","timestamp":1773046725000},"page":"2070","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Metabolic Myopathies and HyperCKemia in Adulthood: A Clinical Approach to Diagnosis and Management"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7625-0482","authenticated-orcid":false,"given":"Loai A.","family":"Shakerdi","sequence":"first","affiliation":[{"name":"School of Public Health, University College Dublin, D04 V1W8 Dublin, Ireland"},{"name":"National Centre for Inherited Metabolic Disorders, Mater Misericordiae University Hospital, Eccles St, Phibsborough, D07 R2WY Dublin, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,3,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.nmd.2011.04.007","article-title":"Variation of serum creatine kinase (ck) levels and prevalence of persistent hyperckemia in a norwegian normal population. The troms\u00f8 study","volume":"21","author":"Lilleng","year":"2011","journal-title":"Neuromuscul. Disord."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3949\/ccjm.83a.14120","article-title":"Approach to asymptomatic creatine kinase elevation","volume":"83","author":"Oddis","year":"2016","journal-title":"Clevel. Clin. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Miernik, S., Matusiewicz, A., and Olesi\u0144ska, M. (2024). Drug-induced myopathies: A comprehensive review and update. Biomedicines, 12.","DOI":"10.3390\/biomedicines12050987"},{"key":"ref_4","first-page":"e60477","article-title":"Immune-mediated necrotizing myopathy associated with anti-signal recognition particle antibody complicated with acute respiratory distress syndrome: A report of two cases","volume":"16","author":"Fang","year":"2024","journal-title":"Cureus"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1017\/cjn.2017.286","article-title":"Next-generation sequencing to diagnose muscular dystrophy, rhabdomyolysis, and hyperckemia","volume":"45","author":"Wu","year":"2018","journal-title":"Can. J. Neurol. Sci."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1111\/ene.14553","article-title":"The etiology of rhabdomyolysis: An interaction between genetic susceptibility and external triggers","volume":"28","author":"Kruijt","year":"2021","journal-title":"Eur. J. Neurol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.bbadis.2005.09.004","article-title":"Mitochondrial creatine kinase in human health and disease","volume":"1762","author":"Schlattner","year":"2006","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_8","unstructured":"Aujla, R.S., Zubair, M., and Patel, R. (2025). Creatine phosphokinase. StatPearls, StatPearls Publishing LLC.. Copyright \u00a9 2025."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S1726-4901(10)70019-8","article-title":"Macroenzyme creatine kinase in the era of modern laboratory medicine","volume":"73","author":"Liu","year":"2010","journal-title":"J. Chin. Med. Assoc."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"960363","DOI":"10.1155\/2012\/960363","article-title":"Creatine-kinase- and exercise-related muscle damage implications for muscle performance and recovery","volume":"2012","author":"Baird","year":"2012","journal-title":"J. Nutr. Metab."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"R434","DOI":"10.1152\/ajpregu.1994.266.2.R434","article-title":"Kinetic evaluation of muscle damage during exercise by calculation of amount of creatine kinase released","volume":"266","author":"Volfinger","year":"1994","journal-title":"Am. J. Physiol.-Regul. Integr. Comp. Physiol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e982","DOI":"10.1093\/milmed\/usaa079","article-title":"Biomarkers, creatine kinase, and kidney function of special operation candidates during intense physiological training","volume":"185","author":"Shumway","year":"2020","journal-title":"Mil. Med."},{"key":"ref_13","unstructured":"Rout, P., Chippa, V., and Adigun, R. (2025). Rhabdomyolysis. StatPearls, StatPearls Publishing LLC.. Copyright \u00a9 2025."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"M\u0142ynarska, E., Krzemi\u0144ska, J., Wronka, M., Franczyk, B., and Rysz, J. (2022). Rhabdomyolysis-induced aki (riaki) including the role of COVID-19. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23158215"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.cld.2012.03.006","article-title":"Evaluation of elevated liver enzymes","volume":"16","author":"Lee","year":"2012","journal-title":"Clin. Liver Dis."},{"key":"ref_16","unstructured":"Lala, V., Zubair, M., and Minter, D.A. (2025). Liver function tests. StatPearls, StatPearls Publishing LLC.. Copyright \u00a9 2025."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.3748\/wjg.v26.i10.1020","article-title":"Abnormal liver function tests associated with severe rhabdomyolysis","volume":"26","author":"Lim","year":"2020","journal-title":"World J. Gastroenterol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/j.1365-2125.2007.03001.x","article-title":"Muscular exercise can cause highly pathological liver function tests in healthy men","volume":"65","author":"Pettersson","year":"2008","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1212\/01.CON.0000440660.41675.06","article-title":"Metabolic myopathies","volume":"19","author":"Tobon","year":"2013","journal-title":"Continuum"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1006\/bbrc.1997.6749","article-title":"Glycogen-storage disease type ii (acid maltase deficiency): Identification of a novel small deletion (delcc482+483) in french patients","volume":"235","author":"Nicolino","year":"1997","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/S0140-6736(08)61555-X","article-title":"Pompe\u2019s disease","volume":"372","author":"Reuser","year":"2008","journal-title":"Lancet"},{"key":"ref_22","first-page":"82","article-title":"Clinical features of pompe disease","volume":"32","author":"Manganelli","year":"2013","journal-title":"Acta Myol."},{"key":"ref_23","unstructured":"Adam, M.P., Ardinger, H.H., Pagon, R.A., Wallace, S.E., Bean, L.J.H., Gripp, K.W., Mirzaa, G.M., and Amemiya, A. (1993). Glycogen Storage Disease Type III. GeneReviews((R)), University of Washington."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1007\/s10545-016-9932-2","article-title":"Glycogen storage disease type iii: Diagnosis, genotype, management, clinical course and outcome","volume":"39","author":"Sentner","year":"2016","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_25","unstructured":"Lam, J.R., Anastasopoulou, C., Khattak, Z.E., and Ashraf, M. (2025). Mcardle disease (glycogen storage disease type 5). StatPearls, StatPearls Publishing LLC.. Copyright \u00a9 2025."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1212\/NXG.0000000000000007","article-title":"PFKM gene defect and glycogen storage disease gsdvii with misleading enzyme histochemistry","volume":"1","author":"Auranen","year":"2015","journal-title":"Neurol. Genet."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Chen, Y., Wang, X., Ji, N., Fang, Q., Chang, X., and Liu, M. (2024). Case report: Comprehensive exploration of a novel pfkm mutation in glycogen storage disease type vii. Front. Genet., 15.","DOI":"10.3389\/fgene.2024.1422908"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Candela, E., Montanari, G., Zanaroli, A., Baronio, F., Ortolano, R., Biasucci, G., and Lanari, M. (2025). Understanding glycogen storage disease type ix: A systematic review with clinical focus-why it is not benign and requires vigilance. Genes, 16.","DOI":"10.3390\/genes16050584"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1542\/peds.109.1.99","article-title":"Long-chain 3-hydroxyacyl-coa dehydrogenase deficiency: Clinical presentation and follow-up of 50 patients","volume":"109","author":"Wanders","year":"2002","journal-title":"Pediatrics"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"7904190","DOI":"10.1155\/2020\/7904190","article-title":"Lipin-1 deficiency-associated recurrent rhabdomyolysis and exercise-induced myalgia persisting into adulthood: A case report and review of literature","volume":"2020","author":"Indika","year":"2020","journal-title":"Case Rep. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.jocn.2018.11.023","article-title":"Phenotype of carnitine palmitoyltransferase ii (cpt ii) deficiency: A questionnaire-based survey","volume":"59","author":"Joshi","year":"2019","journal-title":"J. Clin. Neurosci."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1001\/archneur.62.1.37","article-title":"Muscle carnitine palmitoyltransferase ii deficiency: Clinical and molecular genetic features and diagnostic aspects","volume":"62","author":"Deschauer","year":"2005","journal-title":"Arch. Neurol."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Joshi, P.R., and Zierz, S. (2020). Muscle carnitine palmitoyltransferase ii (cpt ii) deficiency: A conceptual approach. Molecules, 25.","DOI":"10.3390\/molecules25081784"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1007\/s10545-009-1126-8","article-title":"Treatment recommendations in long-chain fatty acid oxidation defects: Consensus from a workshop","volume":"32","author":"Spiekerkoetter","year":"2009","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1042\/bj2810021","article-title":"Intracellular compartmentation, structure and function of creatine kinase isoenzymes in tissues with high and fluctuating energy demands: The \u2018phosphocreatine circuit\u2019 for cellular energy homeostasis","volume":"281","author":"Wallimann","year":"1992","journal-title":"Biochem. J."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1023\/A:1006840508139","article-title":"Functional coupling of creatine kinases in muscles: Species and tissue specificity","volume":"184","author":"Kuznetsov","year":"1998","journal-title":"Mol. Cell Biochem."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s13023-015-0236-7","article-title":"Clinical outcome, biochemical and therapeutic follow-up in 14 austrian patients with long-chain 3-hydroxy acyl coa dehydrogenase deficiency (lchadd)","volume":"10","author":"Karall","year":"2015","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1515\/CCLM.2010.151","article-title":"Rhabdomyolysis: Historical background, clinical, diagnostic and therapeutic features","volume":"48","author":"Cervellin","year":"2010","journal-title":"Clin. Chem. Lab. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.nmd.2022.06.010","article-title":"Two tales of lpin1 deficiency: From fatal rhabdomyolysis to favorable outcome of acute compartment syndrome","volume":"32","author":"Kahraman","year":"2022","journal-title":"Neuromuscul. Disord."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1111\/ene.14402","article-title":"Adult-onset very-long-chain acyl-coa dehydrogenase deficiency (vlcadd)","volume":"27","author":"Fatehi","year":"2020","journal-title":"Eur. J. Neurol."},{"key":"ref_41","unstructured":"Adam, M.P., Bick, S., Mirzaa, G.M., Pagon, R.A., Wallace, S.E., and Amemiya, A. (1993). Primary carnitine deficiency. Genereviews(\u00ae), University of Washington. Copyright \u00a9 1993\u20132026."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.4103\/0366-6999.159360","article-title":"Progress in diagnosing mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes","volume":"128","author":"Wang","year":"2015","journal-title":"Chin. Med. J."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.nmd.2020.02.020","article-title":"Progressive external ophthalmoplegia due to a recurrent de novo m.15990c>t mt-tp (mt-trnapro) gene variant","volume":"30","author":"Joshi","year":"2020","journal-title":"Neuromuscul. Disord."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"35970","DOI":"10.1038\/srep35970","article-title":"Insertion of a knockout-first cassette in ampd1 gene leads to neonatal death by disruption of neighboring genes expression","volume":"6","author":"Pan","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_45","first-page":"445","article-title":"Myoadenylate deaminase deficiency: A frequent cause of muscle pain a case detected by exercise testing","volume":"75","author":"Lim","year":"2017","journal-title":"Ann. Biol. Clin."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"e70493","DOI":"10.1111\/ene.70493","article-title":"Ean 2024 guideline on the diagnostic approach to oligo\/asymptomatic hyperckemia","volume":"33","author":"Kyriakides","year":"2026","journal-title":"Eur. J. Neurol."},{"key":"ref_47","first-page":"110","article-title":"Asymptomatic or minimally symptomatic hyperCKemia: Histopathologic correlates","volume":"8","author":"Dabby","year":"2006","journal-title":"Isr. Med. Assoc. J."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"de Marchi, R., Nalin, T., Sperb-Ludwig, F., Pinheiro, F.C., Schwartz, I.V.D., and Steiner, C.E. (2023). Glycogen storage disease: Expert opinion on clinical diagnosis revisited after molecular testing. Genes, 14.","DOI":"10.3390\/genes14122219"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s10545-016-9915-3","article-title":"Unique plasma metabolomic signatures of individuals with inherited disorders of long-chain fatty acid oxidation","volume":"39","author":"McCoin","year":"2016","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Ruiz-Sala, P., and Pe\u00f1a-Quintana, L. (2021). Biochemical markers for the diagnosis of mitochondrial fatty acid oxidation diseases. J. Clin. Med., 10.","DOI":"10.3390\/jcm10214855"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1124\/pharmrev.121.000408","article-title":"Acylcarnitines: Nomenclature, biomarkers, therapeutic potential, drug targets, and clinical trials","volume":"74","author":"Dambrova","year":"2022","journal-title":"Pharmacol. Rev."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"McCann, M.R., George De la Rosa, M.V., Rosania, G.R., and Stringer, K.A. (2021). L-carnitine and acylcarnitines: Mitochondrial biomarkers for precision medicine. Metabolites, 11.","DOI":"10.3390\/metabo11010051"},{"key":"ref_53","first-page":"19.3.1","article-title":"Evaluation of the mitochondrial respiratory chain and oxidative phosphorylation system using polarography and spectrophotometric enzyme assays","volume":"19","author":"Barrientos","year":"2009","journal-title":"Curr. Protoc. Hum. Genet."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1212\/WNL.56.12.1733","article-title":"A non-ischemic forearm exercise test for the screening of patients with exercise intolerance","volume":"56","author":"Hogrel","year":"2001","journal-title":"Neurology"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"S147","DOI":"10.37765\/ajmc.2020.88480","article-title":"Long-chain fatty acid oxidation disorders and current management strategies","volume":"26","author":"Vockley","year":"2020","journal-title":"Am. J. Manag. Care"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1002\/mus.27840","article-title":"Diagnosis and management of metabolic myopathies","volume":"68","author":"Bhai","year":"2023","journal-title":"Muscle Nerve"},{"key":"ref_57","first-page":"E733","article-title":"Glucose and insulin-induced inhibition of fatty acid oxidation: The glucose-fatty acid cycle reversed","volume":"270","author":"Sidossis","year":"1996","journal-title":"Am. J. Physiol."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Pe\u00f1a-Quintana, L., and Correcher-Medina, P. (2024). Nutritional management of patients with fatty acid oxidation disorders. Nutrients, 16.","DOI":"10.3390\/nu16162707"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/ajmg.c.30087","article-title":"Disorders of carnitine transport and the carnitine cycle","volume":"142c","author":"Longo","year":"2006","journal-title":"Am. J. Med. Genet. C Semin. Med. Genet."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Kochan, Z., and Karbowska, J. (2025). How genes meet diet in lchad deficiency: Nutrigenomics of fatty acid oxidation disorder. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms262010140"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ymgme.2015.09.004","article-title":"Disorders of carnitine biosynthesis and transport","volume":"116","author":"Scaglia","year":"2015","journal-title":"Mol. Genet. Metab."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Amaral, A.U., and Wajner, M. (2020). Recent advances in the pathophysiology of fatty acid oxidation defects: Secondary alterations of bioenergetics and mitochondrial calcium homeostasis caused by the accumulating fatty acids. Front. Genet., 11.","DOI":"10.3389\/fgene.2020.598976"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1007\/s11940-009-0046-0","article-title":"A modern approach to the treatment of mitochondrial disease","volume":"11","author":"Parikh","year":"2009","journal-title":"Curr. Treat. Options Neurol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1007\/s13311-018-0655-y","article-title":"Pompe disease: From basic science to therapy","volume":"15","author":"Kohler","year":"2018","journal-title":"Neurotherapeutics"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/01.gim.0000218152.87434.f3","article-title":"Pompe disease diagnosis and management guideline","volume":"8","author":"Kishnani","year":"2006","journal-title":"Genet. Med."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Massimino, E., Amoroso, A.P., Lupoli, R., Rossi, A., and Capaldo, B. (2023). Nutritional management of glycogen storage disease type iii: A case report and a critical appraisal of the literature. Front. Nutr., 10.","DOI":"10.3389\/fnut.2023.1178348"},{"key":"ref_67","first-page":"58","article-title":"Pharmacological and nutritional treatment trials in McArdle disease","volume":"26","author":"Quinlivan","year":"2007","journal-title":"Acta Myol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/j.nmd.2021.10.006","article-title":"Clinical practice guidelines for glycogen storage disease v & vii (mcardle disease and tarui disease) from an international study group","volume":"31","author":"Lucia","year":"2021","journal-title":"Neuromuscul. Disord."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1056\/NEJM199102073240603","article-title":"Glucose-induced exertional fatigue in muscle phosphofructokinase deficiency","volume":"324","author":"Haller","year":"1991","journal-title":"N. Engl. J. Med."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Simil\u00e4, M.E., Auranen, M., and Piiril\u00e4, P.L. (2020). Beneficial effects of ketogenic diet on phosphofructokinase deficiency (glycogen storage disease type vii). Front. Neurol., 11.","DOI":"10.3389\/fneur.2020.00057"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1093\/advances\/nmz092","article-title":"Dietary management of the glycogen storage diseases: Evolution of treatment and ongoing controversies","volume":"11","author":"Ross","year":"2020","journal-title":"Adv. Nutr."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"9798","DOI":"10.4081\/ejtm.2021.9798","article-title":"Exercise, nutrition and enzyme replacement therapy are efficacious in adult pompe patients: Report from epoc consortium","volume":"31","author":"Angelini","year":"2021","journal-title":"Eur. J. Transl. Myol."},{"key":"ref_73","unstructured":"Adam, M.P., Mirzaa, G.M., Pagon, R.A., Wallace, S.E., Bean, L.J.H., Gripp, K.W., and Amemiya, A. (1993). Carnitine palmitoyltransferase ii deficiency. GeneReviews(\u00ae), University of Washington. Copyright \u00a9 1993\u20132023."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ymgme.2020.10.001","article-title":"Nutrition management guideline for very-long chain acyl-coa dehydrogenase deficiency (vlcad): An evidence- and consensus-based approach","volume":"131","author":"Sowa","year":"2020","journal-title":"Mol. Genet. Metab."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1023\/A:1005437616934","article-title":"Dietary management of long-chain 3-hydroxyacyl-coa dehydrogenase deficiency (lchadd). A case report and survey","volume":"22","author":"Gillingham","year":"1999","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1002\/jimd.12037","article-title":"Proposal for an individualized dietary strategy in patients with very long-chain acyl-coa dehydrogenase deficiency","volume":"42","author":"Bleeker","year":"2019","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_77","first-page":"e32709","article-title":"Arginine for the treatment of mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes: A systematic review","volume":"14","author":"Argudo","year":"2022","journal-title":"Cureus"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1007\/s13730-025-00992-5","article-title":"Taurine supplementation improves physical activity level in a hemodialysis patient with mitochondrial disease: A case report","volume":"14","author":"Yoshida","year":"2025","journal-title":"CEN Case Rep."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1097\/MOP.0000000000000954","article-title":"Mitochondrial medicine therapies: Rationale, evidence, and dosing guidelines","volume":"32","author":"Barcelos","year":"2020","journal-title":"Curr. Opin. Pediatr."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.bbabio.2005.11.009","article-title":"Riboflavin enhances the assembly of mitochondrial cytochrome c oxidase in C. elegans nadh-ubiquinone oxidoreductase mutants","volume":"1757","author":"Grad","year":"2006","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/mus.880160205","article-title":"Plasma carnitine insufficiency and effectiveness of l-carnitine therapy in patients with mitochondrial myopathy","volume":"16","author":"Campos","year":"1993","journal-title":"Muscle Nerve"},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Marshall, R.P., Droste, J.N., Giessing, J., and Kreider, R.B. (2022). Role of creatine supplementation in conditions involving mitochondrial dysfunction: A narrative review. Nutrients, 14.","DOI":"10.3390\/nu14030529"},{"key":"ref_83","first-page":"1","article-title":"Therapies for mitochondrial diseases and current clinical trials","volume":"122","author":"Zarante","year":"2017","journal-title":"Mol. Genet. Metab."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1007\/BF01785710","article-title":"Myoadenylate deaminase deficiency: Successful symptomatic therapy by high dose oral administration of ribose","volume":"64","author":"Reiter","year":"1986","journal-title":"Klin. Wochenschr."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Paoletti, M., Pichiecchio, A., Cotti Piccinelli, S., Tasca, G., Berardinelli, A.L., Padovani, A., and Filosto, M. (2019). Advances in quantitative imaging of genetic and acquired myopathies: Clinical applications and perspectives. Front. Neurol., 10.","DOI":"10.3389\/fneur.2019.00078"},{"key":"ref_86","first-page":"7","article-title":"The art of muscle biopsy in the new genetic era: A narrative review","volume":"13","author":"Nilipour","year":"2019","journal-title":"Iran. J. Child. Neurol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.nmd.2017.04.013","article-title":"Misdiagnosis is an important factor for diagnostic delay in mcardle disease","volume":"27","author":"Scalco","year":"2017","journal-title":"Neuromuscul. Disord."},{"key":"ref_88","first-page":"39","article-title":"Diagnostic delay in late-onset Pompe disease among Chinese patients: A retrospective study","volume":"65","author":"Yue","year":"2024","journal-title":"JIMD Rep."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"e597","DOI":"10.1212\/NXG.0000000000000597","article-title":"Diagnosing mitochondrial disorders remains challenging in the omics era","volume":"7","author":"Forny","year":"2021","journal-title":"Neurol. Genet."},{"key":"ref_90","first-page":"61","article-title":"Treatment of glycogenosys type V (McArdle disease) with creatine and ketogenic diet with clinical scores and with 31P-MRS on working leg muscle","volume":"26","author":"Vorgerd","year":"2007","journal-title":"Acta Myol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1001\/archneur.57.7.956","article-title":"Creatine therapy in myophosphorylase deficiency (mcardle disease): A placebo-controlled crossover trial","volume":"57","author":"Vorgerd","year":"2000","journal-title":"Arch. Neurol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1001\/archneur.59.1.97","article-title":"Effect of high-dose creatine therapy on symptoms of exercise intolerance in mcardle disease: Double-blind, placebo-controlled crossover study","volume":"59","author":"Vorgerd","year":"2002","journal-title":"Arch. Neurol."},{"key":"ref_93","first-page":"e70000","article-title":"Mcardle\u2019s disease: A differential diagnosis of metabolic myopathies","volume":"16","author":"Nascimento","year":"2024","journal-title":"Cureus"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"luaf217","DOI":"10.1210\/jcemcr\/luaf217","article-title":"Improvement of symptoms in a patient with glycogen storage disease through nutritional guidance and exercise therapy","volume":"3","author":"Morita","year":"2025","journal-title":"JCEM Case Rep."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1007\/s00415-025-13405-5","article-title":"Low-carbohydrate ketogenic diet in mc ardle\u2019s disease: A single-blinded randomized controlled trial","volume":"272","author":"Martinuzzi","year":"2025","journal-title":"J. Neurol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1056\/NEJMoa031836","article-title":"The effect of oral sucrose on exercise tolerance in patients with mcardle\u2019s disease","volume":"349","author":"Vissing","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1002\/mus.22290","article-title":"Confirmation of the efficacy of vitamin b6 supplementation for mcardle disease by follow-up muscle biopsy","volume":"45","author":"Sato","year":"2012","journal-title":"Muscle Nerve"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.ymgme.2015.10.005","article-title":"Anaplerotic treatment of long-chain fat oxidation disorders with triheptanoin: Review of 15 years experience","volume":"116","author":"Roe","year":"2015","journal-title":"Mol. Genet. Metab."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.nmd.2022.01.012","article-title":"No effect of triheptanoin in patients with phosphofructokinase deficiency","volume":"32","author":"Madsen","year":"2022","journal-title":"Neuromuscul. Disord."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1002\/acn3.50863","article-title":"No effect of triheptanoin on exercise performance in mcardle disease","volume":"6","author":"Madsen","year":"2019","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1007\/s10545-009-1125-9","article-title":"Management and outcome in 75 individuals with long-chain fatty acid oxidation defects: Results from a workshop","volume":"32","author":"Spiekerkoetter","year":"2009","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ymgme.2008.09.008","article-title":"A Delphi clinical practice protocol for the management of very long chain acyl-coa dehydrogenase deficiency","volume":"96","author":"Arnold","year":"2009","journal-title":"Mol. Genet. Metab."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.spen.2008.05.008","article-title":"Mitochondrial fatty-acid oxidation disorders","volume":"15","author":"Kompare","year":"2008","journal-title":"Semin. Pediatr. Neurol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1006\/mgme.1999.2938","article-title":"Carnitine palmitoyltransferase deficiencies","volume":"68","author":"Bonnefont","year":"1999","journal-title":"Mol. Genet. Metab."},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Maines, E., Gugelmo, G., Vitturi, N., Dianin, A., Rubert, L., Piccoli, G., Soffiati, M., Cauvin, V., and Franceschi, R. (2025). A focus on the role of dietary treatment in the prevention of retinal dysfunction in patients with long-chain 3-hydroxyacyl-coa dehydrogenase deficiency: A systematic review. Children, 12.","DOI":"10.3390\/children12030374"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/S1096-7192(03)00073-8","article-title":"Optimal dietary therapy of long-chain 3-hydroxyacyl-coa dehydrogenase deficiency","volume":"79","author":"Gillingham","year":"2003","journal-title":"Mol. Genet. Metab."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1203\/00006450-199104000-00016","article-title":"Long-chain 3-hydroxyacyl-coa dehydrogenase deficiency","volume":"29","author":"Jackson","year":"1991","journal-title":"Pediatr. Res."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/BF01955905","article-title":"Long-chain 3-hydroxyacyl-coenzyme a dehydrogenase deficiency\u2014Diagnosis, plasma carnitine fractions and management in a further patient","volume":"152","author":"Moore","year":"1993","journal-title":"Eur. J. Pediatr."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1007\/s00431-025-06216-3","article-title":"The effect of triheptanoin treatment on clinical and laboratory outcomes in patients with long-chain fatty acid oxidation disorder","volume":"184","author":"Er","year":"2025","journal-title":"Eur. J. Pediatr."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1186\/s13052-024-01782-y","article-title":"Triheptanoin in patients with long-chain fatty acid oxidation disorders: Clinical experience in Italy","volume":"50","author":"Porta","year":"2024","journal-title":"Ital. J. Pediatr."},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Barros, C.D.S., Livramento, J.B., Mouro, M.G., Higa, E.M.S., Moraes, C.T., and Tengan, C.H. (2021). L-arginine reduces nitro-oxidative stress in cultured cells with mitochondrial deficiency. Nutrients, 13.","DOI":"10.3390\/nu13020534"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"e2318","DOI":"10.1212\/WNL.0000000000200299","article-title":"L-arginine in mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes","volume":"98","author":"Stefanetti","year":"2022","journal-title":"Neurology"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.celrep.2017.12.051","article-title":"Defective mitochondrial trna taurine modification activates global proteostress and leads to mitochondrial disease","volume":"22","author":"Fakruddin","year":"2018","journal-title":"Cell Rep."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1136\/jnnp-2018-317964","article-title":"Taurine supplementation for prevention of stroke-like episodes in melas: A multicentre, open-label, 52-week phase III trial","volume":"90","author":"Ohsawa","year":"2019","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"100025","DOI":"10.1016\/j.bdcasr.2024.100025","article-title":"Familial hyperckemia with exercise-induced myalgia associated with a novel missense variant in ryr1","volume":"2","author":"Hiraide","year":"2024","journal-title":"Brain Dev. Case Rep."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.nmd.2013.03.008","article-title":"Mutations in ryr1 are a common cause of exertional myalgia and rhabdomyolysis","volume":"23","author":"Dlamini","year":"2013","journal-title":"Neuromuscul. Disord."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1002\/mus.20525","article-title":"Familial idiopathic hyper-ck-emia: An underrecognized condition","volume":"33","author":"Capasso","year":"2006","journal-title":"Muscle Nerve"},{"key":"ref_118","unstructured":"Rowland, L., Willner, J., DiMauro, S., Miranda, A., Angelini, C., Danieli, G., and Fontanari, D. (1980). Muscular Dystrophy-Advances and New Trends, Excerpta Medica."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/5\/2070\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T09:25:57Z","timestamp":1773048357000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/5\/2070"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,9]]},"references-count":118,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["jcm15052070"],"URL":"https:\/\/doi.org\/10.3390\/jcm15052070","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,9]]}}}